Clinical trials: Thoracic Tumors
Non-Small Cell Lung Cancer, Solid Tumors
A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR
The safety, tolerability and recommended phase 2 dose (RP2D) of the combination of gefitinib and BKM120 will be determined.
- Trial name
- BKM120 (NCT01570296)
- Testing
- Gefitinib and BKM120
- Where
- Singapore
- Volunteers
- 38 people
- Sponsor
- National Cancer Centre, Singapore
Non Small Cell Lung Cancer
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
This is a phase I/II study. The phase I portion of the study will determine the maximum tolerated dose of bortezomib when administered in combination with carboplatin \& docetaxel and to determine the efficacy of the combination…
- Trial name
- NCT00714246
- Testing
- Bortezomib, Carboplatin, Docetaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Milton S. Hershey Medical Center
Lung Neoplasm
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation.
- Trial name
- VALOR (NCT02984761)
- Testing
- Stereotactic Radiotherapy, Anatomic Pulmonary Resection
- Where
- 17 sites in United States
- Volunteers
- 670 people
- Sponsor
- VA Office of Research and Development
Small-cell Lung Cancer
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.
- Trial name
- NCT00286169
- Testing
- Amrubicin Hydrochloride
- Where
- 8 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Lung Cancer
A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions
Theobjectiveofthisstudyistoevaluatethecomparativebioavailabilitybetween: ErlotinibHCl150mgTablets(Novopharm Limited,Canada)and Tarceva® 150mgTablets(Hoffmann-LaRocheLimited,Canada)…
- Trial name
- NCT04145570
- Testing
- Erlotinib HCl 150 mg, Tarceva®
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Quadras Scientific Solutions
Lung Cancer
Postoperative Rehabilitation in Operation for LUng CAncer (PROLUCA)
Purpose The purpose of the PROLUCA study is to investigate the efficacy of early postoperative rehabilitation in a non-hospital setting in patients with operable lung cancer, with focus on exercise training.
- Trial name
- PROLUCA (NCT02439073)
- Testing
- Rehabilitation
- Where
- Denmark
- Volunteers
- 235 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lung Cancer (Diagnosis), Pulmonary Nodule Persistent
Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules
Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant…
- Trial name
- NCT07047573
- Testing
- PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Zhao Jun
Neoplasm Malignant, Breast Cancer
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Primary Objectives: Part 1 (Dose Escalation) To determine the MTD/maximum administered dose (MAD) of SAR443216 administered as a single agent in participants with HER2 expressing solid tumors and determine the RD(s) for…
- Conditions
- Neoplasm Malignant, Breast Cancer, Lung Neoplasm Malignant, Gastric Cancer
- Trial name
- NCT05013554
- Testing
- SAR443216 IV, SAR443216 SC
- Where
- 11 sites in United States, Belgium and 4 more
- Volunteers
- 44 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK -positive, or ROS1-positive non-small cell lung cancer (NSCLC)
- Trial name
- NCT04641754
- Testing
- WX-0593 Tablets
- Where
- 41 sites in China
- Volunteers
- 176 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-small Cell Lung Cancer
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
This is a single center, prospective and observational study conducted in three stages to predict the NSCLC lymph node metastasis based on ctDNA/specific methylation molecular features combined with PET-CT imaging features and…
- Trial name
- NCT06358222
- Testing
- Blood ctDNA + methylation + PET-CT and Postoperative pathology, MRD+ methylation (or combined with PET-CT) and Invasive mediastinoscopy /EBUS-TBNA, Intraoperative lymph node dissection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Pulmonary Nodules
Robotic-Assisted Bronchoscopy-Guided Synchronous Biopsy and Radiofrequency Ablation for Pulmonary Nodules
This is a prospective, single-arm, open-label clinical study. The primary study objective is to evaluate the feasibility of synchronous biopsy and radiofrequency ablation for pulmonary nodules under robotic-assisted bronchoscopy.
- Trial name
- NCT07545057
- Testing
- Robotic-assisted bronchoscopy-guided synchronous biopsy and radiofrequency ablation for pulmonary nodules
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shanghai Chest Hospital
Advanced Melanoma, Non-small Cell Lung Cancer
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
This trial is a phase 1/1b study to evaluate the safety, efficacy, and tolerability of APX005M in combination with nivolumab and cabiralizumab.
- Conditions
- Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03502330
- Testing
- APX005M, Cabiralizumab, Nivolumab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Yale University
Nonsmall Cell Lung Cancer
Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer
This study will treat patients with advanced NSCLC who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may…
- Trial name
- JACKPOT1 (NCT03450330)
- Testing
- AZD4205
- Where
- 4 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Dizal Pharmaceuticals
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms
- Trial name
- PICSI-H (NCT04283994)
- Testing
- Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 756 people
- Sponsor
- University of Washington
Carcinoma, Non-Small-Cell Lung
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have…
- Trial name
- NCT00522145
- Testing
- XL647
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Kadmon Corporation, LLC
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Post Operative Complication, Pulmonary, Lung Cancer
Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD
To test the hypothesis that nebulized Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD.
- Conditions
- Post Operative Complication, Pulmonary, Lung Cancer, COPD
- Trial name
- NCT02504801
- Testing
- Budesonide
- Volunteers
- 73 people
- Sponsor
- Xiuyi Zhi
Metastatic Non-Small Cell Lung Cancer
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
The purpose of this expanded access program (EAP) is to provide amivantamab for the treatment of participants with metastatic non-small cell lung cancer who have epidermal growth factor receptor exon 20 insertion mutations, and…
- Trial name
- NCT04599712
- Testing
- Amivantamab
- Sponsor
- Janssen Research & Development, LLC
Non-Small Cell Lung Cancer (NSCLC)
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
- Trial name
- NCT01951157
- Testing
- Docetaxel, Gemcitabine, Lurbinectedin (PM01183)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- PharmaMar
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
- Trial name
- ALERT-lung (NCT03445000)
- Testing
- Alectinib
- Where
- 19 sites in Belgium, Ireland and 4 more
- Volunteers
- 14 people
- Sponsor
- ETOP IBCSG Partners Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.